Emerging data on calcium-channel blockers: The COHORT study

Alberto Zanchetti

Research output: Contribution to journalArticle

Abstract

Multiple studies have demonstrated dihydropyridine calcium-channel blocker (CCB) therapy to be appropriate for the treatment of hypertension, as is reflected in treatment guidelines such as the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure in the United States and the 1999 World Health Organization-International Society of Hypertension report. As with any drug class, successful treatment with CCBs depends on good patient compliance, which often hinges on drug tolerability. The differing characteristics among the various generations of CCBs may contribute to some compounds demonstrating superior tolerability. To test this hypothesis, the COHORT trial (named for the large group of participants) was undertaken in 828 elderly hypertensive patients aged ≥ 60 years. This trial investigated the possible differences in patient tolerability between the third-generation agent amlodipine and the latest-generation agents lercanidipine and lacidipine. The primary endpoint of the study was the percentage of patients reporting edema, the most common side effect associated with CCB therapy. The study results indicated that while all three treatments were similarly efficacious in lowering blood pressure, lercanidipine and lacidipine were much better tolerated than amlodipine whether they were used as single agents or as initial therapy combined with other antihypertensive drugs. These newest-generation dihydropyridine CCBs offer the potential to reduce side effects, improve patient compliance, and ultimately help patients reach target blood pressures as recommended by the aforementioned guidelines.

Original languageEnglish
JournalClinical Cardiology
Volume26
Issue number2 SUPPL.
Publication statusPublished - Feb 1 2003

Fingerprint

Calcium Channel Blockers
Amlodipine
Therapeutics
Patient Compliance
Guidelines
Blood Pressure
Hypertension
Pharmaceutical Preparations
Antihypertensive Agents
Edema

Keywords

  • Amlodipine
  • Edema
  • Essential hypertension
  • Lacidipine
  • Lercanidipine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Emerging data on calcium-channel blockers : The COHORT study. / Zanchetti, Alberto.

In: Clinical Cardiology, Vol. 26, No. 2 SUPPL., 01.02.2003.

Research output: Contribution to journalArticle

Zanchetti, Alberto. / Emerging data on calcium-channel blockers : The COHORT study. In: Clinical Cardiology. 2003 ; Vol. 26, No. 2 SUPPL.
@article{e08812bc12e149ff97d53ad73c9cc6b2,
title = "Emerging data on calcium-channel blockers: The COHORT study",
abstract = "Multiple studies have demonstrated dihydropyridine calcium-channel blocker (CCB) therapy to be appropriate for the treatment of hypertension, as is reflected in treatment guidelines such as the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure in the United States and the 1999 World Health Organization-International Society of Hypertension report. As with any drug class, successful treatment with CCBs depends on good patient compliance, which often hinges on drug tolerability. The differing characteristics among the various generations of CCBs may contribute to some compounds demonstrating superior tolerability. To test this hypothesis, the COHORT trial (named for the large group of participants) was undertaken in 828 elderly hypertensive patients aged ≥ 60 years. This trial investigated the possible differences in patient tolerability between the third-generation agent amlodipine and the latest-generation agents lercanidipine and lacidipine. The primary endpoint of the study was the percentage of patients reporting edema, the most common side effect associated with CCB therapy. The study results indicated that while all three treatments were similarly efficacious in lowering blood pressure, lercanidipine and lacidipine were much better tolerated than amlodipine whether they were used as single agents or as initial therapy combined with other antihypertensive drugs. These newest-generation dihydropyridine CCBs offer the potential to reduce side effects, improve patient compliance, and ultimately help patients reach target blood pressures as recommended by the aforementioned guidelines.",
keywords = "Amlodipine, Edema, Essential hypertension, Lacidipine, Lercanidipine",
author = "Alberto Zanchetti",
year = "2003",
month = "2",
day = "1",
language = "English",
volume = "26",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Emerging data on calcium-channel blockers

T2 - The COHORT study

AU - Zanchetti, Alberto

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Multiple studies have demonstrated dihydropyridine calcium-channel blocker (CCB) therapy to be appropriate for the treatment of hypertension, as is reflected in treatment guidelines such as the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure in the United States and the 1999 World Health Organization-International Society of Hypertension report. As with any drug class, successful treatment with CCBs depends on good patient compliance, which often hinges on drug tolerability. The differing characteristics among the various generations of CCBs may contribute to some compounds demonstrating superior tolerability. To test this hypothesis, the COHORT trial (named for the large group of participants) was undertaken in 828 elderly hypertensive patients aged ≥ 60 years. This trial investigated the possible differences in patient tolerability between the third-generation agent amlodipine and the latest-generation agents lercanidipine and lacidipine. The primary endpoint of the study was the percentage of patients reporting edema, the most common side effect associated with CCB therapy. The study results indicated that while all three treatments were similarly efficacious in lowering blood pressure, lercanidipine and lacidipine were much better tolerated than amlodipine whether they were used as single agents or as initial therapy combined with other antihypertensive drugs. These newest-generation dihydropyridine CCBs offer the potential to reduce side effects, improve patient compliance, and ultimately help patients reach target blood pressures as recommended by the aforementioned guidelines.

AB - Multiple studies have demonstrated dihydropyridine calcium-channel blocker (CCB) therapy to be appropriate for the treatment of hypertension, as is reflected in treatment guidelines such as the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure in the United States and the 1999 World Health Organization-International Society of Hypertension report. As with any drug class, successful treatment with CCBs depends on good patient compliance, which often hinges on drug tolerability. The differing characteristics among the various generations of CCBs may contribute to some compounds demonstrating superior tolerability. To test this hypothesis, the COHORT trial (named for the large group of participants) was undertaken in 828 elderly hypertensive patients aged ≥ 60 years. This trial investigated the possible differences in patient tolerability between the third-generation agent amlodipine and the latest-generation agents lercanidipine and lacidipine. The primary endpoint of the study was the percentage of patients reporting edema, the most common side effect associated with CCB therapy. The study results indicated that while all three treatments were similarly efficacious in lowering blood pressure, lercanidipine and lacidipine were much better tolerated than amlodipine whether they were used as single agents or as initial therapy combined with other antihypertensive drugs. These newest-generation dihydropyridine CCBs offer the potential to reduce side effects, improve patient compliance, and ultimately help patients reach target blood pressures as recommended by the aforementioned guidelines.

KW - Amlodipine

KW - Edema

KW - Essential hypertension

KW - Lacidipine

KW - Lercanidipine

UR - http://www.scopus.com/inward/record.url?scp=0037311820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037311820&partnerID=8YFLogxK

M3 - Article

C2 - 12622322

AN - SCOPUS:0037311820

VL - 26

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 2 SUPPL.

ER -